RxDoctor Payments Data

Brian Phung, DO

Family Medicine · Columbia, SCNPI 1588223382

Payments from drug & device makers

$2,599in general payments, 2019–2025

Across 113 payments — averaging $23.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$437
  • Amgen$266
  • Novo Nordisk$249
  • AstraZeneca$218
  • Teva Pharmaceuticals USA, Inc.$206
  • Lilly USA, LLC$186
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$2,599100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,599 in reported general payments places this provider in the 75th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$23,464
Medicare patients
47
Services billed
300

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin26$39,043
RybelsusSemaglutide11$25,989
JanuviaSitagliptin Phosphate16$18,617
VascepaIcosapent Ethyl27$14,192
TrulicityDulaglutide14$13,810
Celecoxib108$8,313
Pantoprazole Sodium48$4,355
Atorvastatin Calcium324$3,956
Fluticasone Propionate176$2,538
Losartan Potassium200$2,008
Ventolin HfaAlbuterol Sulfate28$1,777
Amlodipine Besylate254$1,770
Omeprazole139$1,640
Metformin Hcl167$1,522
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,490

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$22$39,04326 claims
Novo NordiskRybelsus$249$25,98911 claims
MerckJanuvia$83$18,61716 claims
Lilly USA, LLCTrulicity$186$13,81014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →